Kleefstra syndrome is a rare genetic condition that affects development and involves many body systems. Children with Kleefstra syndrome exhibit features of autism, developmental delay, communication difficulties, and low muscle tone (hypotonia). The condition is caused by a mutation in a gene called EHMT1 or the deletion of a specific region of chromosome 9 that includes EHMT1.

Biometric-Guided TMS has shown some early promise in the treatment of Autism Spectrum Disorder (ASD), and based on the success of a Kleefstra Syndrome case there are plans to conduct a collaborative clinical trial between Wave Neuroscience, Boston Children's Hospital, Radboud University Nijmegen Medical Centre (Netherlands), and iDefine (501c3). This session will review scientific principles of the treatment approach, clinical outcomes, and the firsthand experience of a physician who is also the parent of a child with Kleefstra Syndrome.

Erik Won, is is President and Chief Medical Officer of Wave Neuroscience, Inc; a biotechnology company that has innovated breakthrough technologies called Magnetic e-Resonance Therapy (MeRT) and Synchronized Transcranial Magnetic Stimulation (sTMS). These technologies utilize computational neuroanalytics and brain imaging to customize treatment protocols with the aim of restoring optimal neurological function. These represent a form of personalized medicine that are currently in clinical trials sponsored by US Special Operations Command (USSOCOM), Uniformed Services University Health Sciences (USUHS), the Henry M Jackson Foundation, the Department of Veterans Affairs, the University of Southern California (USC) Center for Neurorestoration, and the Texas A&M Institute for Bioscience and Technology, among others.

Erik joined Wave Neuroscience after serving as the Chief Physician and Chief Technology Officer (Health Services) for the Boeing Company. He also served as a US Navy Flight Surgeon for Marine Medium Helicopter Squadron 268, and received the distinction of serving as the ACE (Aviation Combat Element) Flight Surgeon for the 11th Marine Expeditionary Unit (Special Operations Capable). Dr. Won has been published in numerous peer-reviewed journals, textbooks, and presented in numerous academic conferences. He completed his residency at the Harvard OEM combined residency program and was appointed Chief Resident. He received an MPH from the Harvard School of Public Health and MBA from the University of Southern California, Marshall School of Business.

#Neuroscience #neuromodulation #therapy #treatment


🎥 This talk was part of Synchrony 2021 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.

🎥 For more Synchrony 2021 talks and highlights:
https://www.youtube.com/playlist?list=PLDtO9h17tcWd9fk9k9NGO5hzQoRl4a2yw


🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

Synchrony https://synchronysymposium.com/ is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation https://brainfoundation.org/ is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.